Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate CancerRecruiting
NCT07570979Phase 1Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer (mCRPC)
United States, Australia, Japan
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.Recruiting
NCT05948943Phase 2, Phase 3Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
Lymphatic Malformations
United States, Argentina, Australia, Belgium, Czechia +6 more
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN LossTerminated
NCT04251533Phase 3Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Austria, Brazil +25 more
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANRecruiting
NCT07498335Phase 3Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
Berger Disease · Bergers Disease · IgA Nephropathy · Immunoglobulin A Nephropathy
United States, Japan
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Active Not Recruiting
NCT05038735Phase 3Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
Belgium, Bulgaria, Canada, Czechia, Denmark +12 more
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsRecruiting
NCT06726148Phase 1, Phase 2Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Extensive-stage Small Cell Lung Cancer
United States, Australia, Canada, China, Czechia +11 more
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With AsthmaRecruiting
NCT05562466Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Asthma
Argentina, Austria, Brazil, Bulgaria, Colombia +12 more
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.Recruiting
NCT07243002N/AUpdated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
United Kingdom
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)Not Yet Recruiting
NCT07700056Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Pruritus of Unknown Origin
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular EventsActive Not Recruiting
NCT05360446Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Coronary Artery Disease
United States, Argentina, Australia, Belgium, Brazil +13 more
Fabhalta Capsules Specified Drug-use SurveyActive Not Recruiting
NCT07156149N/AUpdated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
C3 Glomerulopathy
Japan
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid LeukemiaTerminated
NCT03874858Phase 2Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myeloid Leukemia
Italy
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL LoweringRecruiting
NCT06865885Phase 4Updated Jul 13, 2026
Sponsor: University of California, San Diego
Drug Interactions · Primary Prevention · Cardiometabolic Syndrome · LDL-Cholersterol Lowering
United States
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate CancerRecruiting
NCT06517719N/AUpdated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer
Germany
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGNRecruiting
NCT05755386Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
IC-MPGN
United States, Argentina, Brazil, Canada, Czechia +18 more
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)Recruiting
NCT05712200Phase 3Updated Jul 13, 2026
Sponsor: Anthos Therapeutics, Inc.
Atrial Fibrillation (AF)
United States, Argentina, Brazil, Bulgaria, Canada +30 more
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainNot Yet Recruiting
NCT07598448N/AUpdated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Complement 3 Glomerulopathy
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's DiseaseRecruiting
NCT07326709Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Huntington Disease
United States, Argentina, Canada, China, Israel +4 more
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)Recruiting
NCT07681271Phase 2Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Papulopustular Rosacea
United States
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.Recruiting
NCT04817618Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
C3G
United States, Argentina, Belgium, Brazil, Canada +14 more
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisRecruiting
NCT07225504Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Secondary Progressive Multiple Sclerosis (SPMS)
United States, Argentina, Australia, Austria, Belgium +27 more
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaActive Not Recruiting
NCT04747613Phase 3Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
United States, Brazil, China, Czechia, France +12 more
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionActive Not Recruiting
NCT06004661Phase 2Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
United States, France, Germany, Italy, Spain
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesRecruiting
NCT06868212Phase 3Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria (CSU)
United States
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed FormulationRecruiting
NCT07626281Phase 1Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Inclisiran Formulation
United States

Previous page Next page